ETH Zurich Discovers New Alzheimer's Trigger and Compound That Blocks It

Alzheimer's disease affects tens of millions worldwide, yet existing drugs target only a narrow slice of its underlying biology. A new study from ETH Zurich, published in Cell Reports Medicine, identifies a previously overlooked driver of the disease and presents an experimental compound that may stop it — with effects that extend beyond the brain.

The research centers on GRK2, a regulatory protein active in the heart and brain. The team discovered that an inactive form of GRK2 accumulates in the brains of people with dementia. Rather than simply being harmless debris, these inactive molecules clump together and attach to mitochondria — the energy-producing structures inside cells — effectively blocking their output. This energy deficit stresses neurons and, critically, triggers increased production of amyloid beta, the protein fragment long linked to Alzheimer's pathology.

This creates a vicious cycle: amyloid beta stresses cells further, generating more inactive GRK2, which forms more aggregates, which deepens mitochondrial dysfunction. None of the currently approved Alzheimer's drugs target this specific loop, making the discovery a potentially significant gap-filler in treatment strategy.

Compound 10, developed after testing multiple candidates in cell cultures and mouse models, interrupts this cycle by preventing GRK2 aggregation. Treated mice showed reduced amyloid deposits, slower nerve cell death, improved mitochondrial function, extended lifespan, better heart function, and fewer signs of biological aging. The breadth of effects suggests GRK2 dysregulation may contribute to systemic aging, not just neurodegeneration.

Important caveats apply. All findings so far are in mice, and the compound has not entered human trials. Translation from mouse models to humans in Alzheimer's research has historically been difficult. Still, the dual impact on brain and heart health, combined with apparent longevity effects, makes Compound 10 a compelling candidate for further investigation. The research was nearly two decades in the making, grounded in human brain tissue analysis from the outset.